Originally developed to manage type 2 diabetes, these tablets have shown potential in helping those who are struggling with weight management
Figure 1 Table 2 Adverse effects and safety risks in phase 3 trials ( AE, adverse event
Rate of Weight Loss The goal of weight loss should be steady and sustainable rather than instant. If an individual is seeing excellent results at a mid-level dose, like 1.0 mg, and is not experiencing hunger, a provider may decide there is no immediate need to increase to the 2.4 mg level
doi: 10.1530/JOE-13-0221 26 Abd El-RadyNMAhmedAAbdel-RadyMMIsmailOI
These include the possibility of mood changes, cognitive issues, and addictive behaviors
Nausea, vomiting, diarrhea, and constipation topped the list, particularly during dose escalation